CAS NO: | 494753-69-4 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
20mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures[1]. Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation ofJak2/Stat3signaling pathway andNF-κB[2]. Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis[1]. Ginsenoside Rk1 induces cellapoptosisby triggering intracellularreactive oxygen species(ROS) generation and blockingPI3K/Aktpathway[3]. | ||||||||||||||||||||||||||||||||||||||||
体外研究 (In Vitro) | Ginsenoside Rk1 (0-40 μM; 6 hours) inhibits MCP-1 and TNF-α mRNA induced by lipopolysaccharide (LPS), expression of IL-1β is inhibited at 40 μM[2].Ginsenoside Rk1 (0-40 μM; 24 hours) inhibits phosphorylation of JAK2 and STAT3 (Tyr705 and Ser727) in LPS-induced RAW264.7 cells in a dose-dependent manner[2].Ginsenoside Rk1 (0-160 μM; 48 hours) results in cell viability significant decrease 75.52 ± 2.51% (40 μM), 52.72 ± 2.54% (80 μM), 17.41 ± 2.94% (120 μM)and 12.63 ± 3.24% (160 μM) compared with control[3].Ginsenoside Rk1 (0-120 μM; 24 hours) increases G0/G1 phase proportion accompanied with S and G2/M phase proportion decrease in MDA-MB-231 cells[3].Ginsenoside Rk1 (0-120 μM; 24 hours) promotes the percentage of apoptotic cells in a dose-dependent manner, exhibits to reduction of cell number with nucleus fragmentation, condensation and apoptotic body formation[3]. RT-PCR[2]
Western Blot Analysis[2]
Cell Viability Assay[3]
Cell Cycle Analysis[3]
Apoptosis Analysis[3]
| ||||||||||||||||||||||||||||||||||||||||
分子量 | 767.00 | ||||||||||||||||||||||||||||||||||||||||
性状 | Solid | ||||||||||||||||||||||||||||||||||||||||
Formula | C42H70O12 | ||||||||||||||||||||||||||||||||||||||||
CAS 号 | 494753-69-4 | ||||||||||||||||||||||||||||||||||||||||
中文名称 | 人参皂苷 | ||||||||||||||||||||||||||||||||||||||||
结构分类 |
| ||||||||||||||||||||||||||||||||||||||||
来源 |
| ||||||||||||||||||||||||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||||||||||||||||||||||||
储存方式 | -20°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) | ||||||||||||||||||||||||||||||||||||||||
溶解性数据 | In Vitro: DMSO : 100 mg/mL(130.38 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|